Fosphenytoin - Sedor Pharmaceuticals

Drug Profile

Fosphenytoin - Sedor Pharmaceuticals

Alternative Names: LGD-461

Latest Information Update: 16 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CyDex Pharmaceuticals
  • Developer Sedor Pharmaceuticals
  • Class Antiepileptic drugs; Hydantoins; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Status epilepticus

Most Recent Events

  • 09 Oct 2017 Fosphenytoin is still at phase III development stage for Status epilepticus in USA (IM), (IV) (Sedor Pharmaceuticals pipeline, October 2017)
  • 08 Dec 2015 Captisol-enabled™ Fosphenytoin licensed to RODES in USA
  • 15 Feb 2011 Fosphenytoin - CyDex Pharmaceuticals is available for licensing as of 15 Feb 2011.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top